论文部分内容阅读
盐酸金刚烷胺本是美国研制成功的用于抗病毒及治疗帕金森综合症的药物。日本汽巴—嘉基公司于1979年发观该药对脑血管障碍后遗症疗效明显,开始对其改善脑梗塞所致的自发性意识低下的新用途进行试验,1987年获得日本批准用于治疗脑梗塞所致的自发性意识低下。将本品用安慰剂作对照,对伴有自发性意识低下的脑血管障碍患者所作的双盲试验结果表明,50～150mg/日,50～150mg/日,给药8周,中等以上有效率本品30.6％,安慰剂为20.6％。
Amantadine hydrochloride was originally developed in the United States for anti-virus and treatment of Parkinson’s disease drugs. Japan’s Ciba-based company in 1979 saw the development of the drug on cerebrovascular disorders sequelae obvious effect, began to improve their cerebral infarction caused by spontaneous hypothyroidism new uses for testing, in 1987 the Japanese approved for the treatment of brain Infarction due to spontaneous low consciousness. The product with placebo as a control, accompanied by spontaneous hypoglycemic cerebrovascular disease in patients with double-blind trial results showed that 50 ~ 150mg / day, 50 ~ 150mg / day, 8 weeks of administration, moderate or more effective This product 30.6%, placebo was 20.6%.